Analyst Price Target is $8.00
▲ +346.93% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Longeveron in the last 3 months. The average price target is $8.00, with a high forecast of $10.00 and a low forecast of $6.00. The average price target represents a 346.93% upside from the last price of $1.79.
Current Consensus is
Buy
The current consensus among 2 investment analysts is to buy stock in Longeveron. This Buy consensus rating has held steady for over two years.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Read More